Flipping a genetic switch in cancer cells may put the brakes on tumor growth, according to new research from Johns Hopkins Medicine.
A team of investigators believe they've come up with a convincing profile for a particular type of tumor cell that could be used as a biomarker for diseases progression as well as a target for drug developers looking to identify a next-gen therapeutic.
RainDance Technologies convinced Myriad Genetics to join its new $20 million Series E financing round, money that will fuel a commercial and manufacturing expansion for its next-generation gene sequencing tools designed to boost diagnostics capacity for various diseases.
Researchers at the University of Rochester Medical Center have developed a way to make a well-known breast cancer drug more effective against aggressive forms of the disease by altering slightly the treatment's target mechanism.
Researchers at the University of California in Los Angeles have created a new way to treat the most aggressive kind of breast cancer using tiny clusters of diamonds.
For women with a very aggressive form of breast cancer, a newly discovered biomarker could indicate how much they might benefit from a recently approved drug.
Dako's push to grow its molecular diagnostics business continues apace. The Danish company gained FDA clearance to start selling a new monoclonal antibody for breast cancer diagnostics.
Work is under way on a diagnostic test that would determine the response of a patient with advanced breast cancer to drug treatment, by measuring the DNA that breaks off from dying tumor cells into the bloodstream.
Navidea Biopharmaceuticals prevailed on the regulatory front with an FDA approval for the company's ($NAVB) imaging drug for patients with breast cancer and melanoma.
Navidea Biopharmaceuticals overcame an initial FDA rejection 6 months ago and finally obtained approval for Lymphoseek, a new radioactive diagnostic imaging agent designed to help map lymph nodes in breast cancer and melanoma patients undergoing surgery.